MedTrace Logo

E7070 in Treating Patients With Stage IV Melanoma

NCT00014625 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2012-07-24

No results posted yet for this study

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

PURPOSE: Phase II trial to study the effectiveness of E7070 in treating patients who have stage IV melanoma.

Conditions

  • Melanoma (Skin)

Interventions

DRUG

indisulam

Sponsors & Collaborators

  • European Organisation for Research and Treatment of Cancer - EORTC

    lead NETWORK

Principal Investigators

  • John F. Smyth, MD · Edinburgh Cancer Centre at Western General Hospital

  • Steinar Aamdal, MD, PhD · Norwegian Radium Hospital

Study Design

Purpose
TREATMENT

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-02-28
Primary Completion
2001-11-30

Countries

  • Austria
  • Belgium
  • France
  • Germany
  • Italy
  • Norway
  • Portugal
  • Switzerland
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00014625 on ClinicalTrials.gov